233 related articles for article (PubMed ID: 27318830)
1. A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification.
Goettsch C; Hutcheson JD; Hagita S; Rogers MA; Creager MD; Pham T; Choi J; Mlynarchik AK; Pieper B; Kjolby M; Aikawa M; Aikawa E
Atherosclerosis; 2016 Aug; 251():109-118. PubMed ID: 27318830
[TBL] [Abstract][Full Text] [Related]
2. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9.
Roche-Molina M; Sanz-Rosa D; Cruz FM; García-Prieto J; López S; Abia R; Muriana FJ; Fuster V; Ibáñez B; Bernal JA
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):50-9. PubMed ID: 25341796
[TBL] [Abstract][Full Text] [Related]
3. Hypercholesterolemia Induced by a PCSK9 Gain-of-Function Mutation Augments Angiotensin II-Induced Abdominal Aortic Aneurysms in C57BL/6 Mice-Brief Report.
Lu H; Howatt DA; Balakrishnan A; Graham MJ; Mullick AE; Daugherty A
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1753-7. PubMed ID: 27470509
[TBL] [Abstract][Full Text] [Related]
4. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
5. A novel mouse model of diabetes, atherosclerosis and fatty liver disease using an AAV8-PCSK9-D377Y injection and dietary manipulation in db/db mice.
Xu M; Wu X; Liu Z; Ding Y; Kong W; Little PJ; Xu S; Weng J
Biochem Biophys Res Commun; 2022 Sep; 622():163-169. PubMed ID: 35868060
[TBL] [Abstract][Full Text] [Related]
6. Expression of a PCSK9 Gain-of-Function Mutation in C57BL/6J Mice to Facilitate Angiotensin II-Induced AAAs.
Sawada H; Daugherty A; Lu HS
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883473
[TBL] [Abstract][Full Text] [Related]
7. Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.
Jarrett KE; Lee C; De Giorgi M; Hurley A; Gillard BK; Doerfler AM; Li A; Pownall HJ; Bao G; Lagor WR
Arterioscler Thromb Vasc Biol; 2018 Sep; 38(9):1997-2006. PubMed ID: 30026278
[TBL] [Abstract][Full Text] [Related]
8. Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation.
Kumar S; Kang DW; Rezvan A; Jo H
Lab Invest; 2017 Aug; 97(8):935-945. PubMed ID: 28504688
[TBL] [Abstract][Full Text] [Related]
9. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ
Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731
[TBL] [Abstract][Full Text] [Related]
10. Reducing Vascular Calcification by Anti-IL-1β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia.
Awan Z; Denis M; Roubtsova A; Essalmani R; Marcinkiewicz J; Awan A; Gram H; Seidah NG; Genest J
Angiology; 2016 Feb; 67(2):157-67. PubMed ID: 25904765
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
[TBL] [Abstract][Full Text] [Related]
12. Local effects of human PCSK9 on the atherosclerotic lesion.
Giunzioni I; Tavori H; Covarrubias R; Major AS; Ding L; Zhang Y; DeVay RM; Hong L; Fan D; Predazzi IM; Rashid S; Linton MF; Fazio S
J Pathol; 2016 Jan; 238(1):52-62. PubMed ID: 26333678
[TBL] [Abstract][Full Text] [Related]
13. The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography.
Awan Z; Denis M; Bailey D; Giaid A; Prat A; Goltzman D; Seidah NG; Genest J
Atherosclerosis; 2011 Dec; 219(2):455-62. PubMed ID: 22051553
[TBL] [Abstract][Full Text] [Related]
14. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
[TBL] [Abstract][Full Text] [Related]
15. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
16. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
[TBL] [Abstract][Full Text] [Related]
17. New Loss-of-Function Mutations in PCSK9 Reduce Plasma LDL Cholesterol.
Meng FH; Liu S; Xiao J; Zhou YX; Dong LW; Li YF; Zhang YQ; Li WH; Wang JQ; Wang Y; Song BL; Ma YT; Fu ZY; Luo J
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1219-1233. PubMed ID: 37165876
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
19. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
[TBL] [Abstract][Full Text] [Related]
20. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
